CAR T cell News and Research

RSS

City of Hope receives $3.7 million from CIRM to develop phase 1 glioblastoma trial

The California Institute for Regenerative Medicine board has awarded City of Hope $3.7 million to develop a phase 1 clinical trial for glioblastoma patients that will genetically engineer their stem cells to better tolerate chemotherapy's side effects, allowing them to receive higher doses of the therapy.

30 Jun 2018

Modified natural killer cells may be new player in CAR-T immunotherapies

Emerging CAR-T immunotherapies leverage modified versions of patient's T-cells to target and kill cancer cells.

29 Jun 2018

AbbVie and Calibr collaborate to develop T-cell therapies aimed at cancer

AbbVie , a research-based global biopharmaceutical company, and Calibr, a nonprofit drug discovery division of Scripps Research, today announced a collaboration to develop T-cell therapies aimed primarily at cancer, including solid tumors.

25 Jun 2018

Cureworks collaborative aims to accelerate development of immunotherapies for pediatric cancer

Seattle Children's, with participating members Children's National Health System, BC Children's Hospital and Children's Hospital Los Angeles, has launched CureWorks, an international collaborative of leading academic children's hospitals determined to accelerate the development of immunotherapy treatments for childhood cancer.

12 Jun 2018

MD Anderson and Amgen collaborate to accelerate early-stage oncology therapies

The University of Texas MD Anderson Cancer Center and Amgen today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies.

1 Jun 2018

Celgene to share new and updated data around novel hematological therapies

Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.

22 May 2018

Obsidian Therapeutics presents preclinical data on regulated IL12 and IL15 programs

Obsidian Therapeutics, Inc., a biotechnology company dedicated to the development of next-generation cell and gene therapies with pharmacologic operating systems, today announced that the company presented preclinical data on its regulated IL12 and IL15 programs at the Annual Meeting of the American Society of Gene and Cell Therapy in Chicago, IL.

17 May 2018

Cancer Center at BIDMC announces launch of new Immunotherapy Institute

The Cancer Center at Beth Israel Deaconess Medical Center today announced the launch of a new clinical and research institute that will build on BIDMC's long history of leadership in immunotherapy and cell therapeutics.

3 May 2018

New T cell biomarker could be much-needed patient-selection tool for CAR T cell therapy

Penn Medicine researchers may have found the reason why some patients with advanced chronic lymphocytic leukemia don't respond to chimeric antigen receptor T cell therapy, and the answer is tied to how primed patients' immune systems are before the therapy is administered.

30 Apr 2018

New CAR-T therapy could provide safer, more effective cancer treatment

There have been few cancer treatments with such a promising future as using the patient's own immune system.

27 Apr 2018

Gene-editing technology enhances T cell immunotherapies for treating cancer

Last year, the Food and Drug Administration approved the first cellular immunotherapies to treat cancer. These therapies involve collecting a patient's own immune cells -- called T cells -- and supercharging them to home in on and attack specific blood cancers, such as hard-to-treat acute lymphoblastic leukemia and non-Hodgkin lymphoma.

6 Mar 2018

Antibiotic use may affect efficacy of cancer immunotherapies

Antibiotic use is known to have a near-immediate impact on our gut microbiota and long-term use may leave us drug-resistant and vulnerable to infection.

2 Mar 2018

Research shows how viruses inactivate immune system, causing cancer

It's no new news that viruses cause cancer. For example, human papillomavirus causes almost all of the more than 500,000 annual worldwide cases of cervical cancer.

2 Mar 2018

New guidelines offer recommendations for assessment, management of immunotherapy side effects

Immunotherapy with immune checkpoint inhibitors is the first of a new generation of immunotherapy treatments, revolutionizing treatment for many different types of cancer. By unleashing the body's immune system to attack cancer, these treatments can send even the most hard-to-treat cancers into lasting remission.

15 Feb 2018

Scientists develop immune-stimulating injections against cancer

A team of researchers have developed two immune-stimulating injections, that removed all traces of cancer when injected directly into solid mouse tumors.

2 Feb 2018

Researchers use immune-mimicking biomaterial scaffolds to fast track T cell therapies

Immunologists and oncologists are harnessing the body's immune system to fight cancers and other diseases with adoptive cell transfer techniques. In a normal immune response, a type of white blood cell known as T cells are instructed by another kind of immune cell called an antigen-presenting cell (APC) to expand their numbers and stay alive.

15 Jan 2018

Researchers develop remote-controlled mechanogenetics system to target and kill cancer cells

A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

15 Jan 2018

CAR T cell therapy shows long-lasting remissions in non-Hodgkin's lymphoma patients

In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) patients.

11 Dec 2017

Two immunotherapy approaches for multiple myeloma show hope

Researchers from the University of Pennsylvania's Abramson Cancer Center have developed two experimental immunotherapy methods that include one chimeric antigen receptor (CAR) T cell therapy for the treatment of multiple myeloma patients who were not responding to other treatments.